Melanotan-1 · Research brief

Is Melanotan-1 Better Than MT-1? (Same Peptide Explained)

Real Peptides Research TeamEditorial

Updated June 22, 20268 min read

48 WORDS

Short answer

Melanotan-1 and MT-1 are the exact same peptide. Alpha-melanocyte-stimulating hormone analog with the amino acid sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. The naming convention differs across suppliers and research contexts, but the molecular structure, receptor binding profile, and biological mechanism remain identical. Any comparison framing these as separate compounds misunderstands peptide nomenclature.

Key takeaways

Melanotan-1 and MT-1 are identical peptides with the same 13-amino-acid sequence. The terms are used interchangeably in research literature with no chemical distinction.
The only meaningful difference between products labeled Melanotan-1 or MT-1 is supplier purity verification, synthesis quality, and post-production handling. Not the peptide structure itself.
Research-grade standards require ≥98% purity via HPLC and sequence confirmation via mass spectrometry. Peptides below 95% purity often contain truncated analogs that reduce MC1R binding affinity by 40–60%.
Solid-phase peptide synthesis (SPPS) produces fewer sequence errors than liquid-phase methods, with 99.9% coupling efficiency yielding 98% final purity compared to 85% at 99.5% efficiency.
Reconstituted Melanotan-1 has a 30-minute half-life at room temperature and retains full potency for 28 days when refrigerated at 2–8°C in bacteriostatic water. Freeze-thaw cycles cause irreversible denaturation.
The most common contaminant in lower-purity batches is des-Nle4 Melanotan-1, a deletion analog that binds MC1R with 40% of full-length peptide affinity. Detectable via HPLC as a shoulder peak.

Our team works directly with research institutions synthesising melanocortin receptor agonists. The confusion stems from inconsistent labeling practices across peptide vendors. Some use 'Melanotan-1' to emphasize the melanogenesis application, while 'MT-1' appears in clinical literature as shorthand. Neither designation indicates a structural variant or improved analog.

Is Melanotan-1 better than MT-1, or are they the same compound?

Melanotan-1 and MT-1 refer to the same 13-amino-acid peptide. An alpha-MSH analog designed to bind melanocortin-1 receptors (MC1R) in melanocytes. The terms are used interchangeably in research literature, with no chemical or functional distinction between them. What differentiates products labeled as Melanotan-1 or MT-1 is supplier purity verification, synthesis method (solid-phase vs liquid-phase), and lyophilisation quality. Not the peptide sequence itself.

Understanding the Melanotan-1 / MT-1 Designation

The name 'Melanotan-1' emerged in the late 1980s during research at the University of Arizona, where scientists synthesized alpha-MSH analogs for melanogenesis studies. 'MT-1' became the clinical shorthand as the compound moved into dermatological trials. Research publications use both terms without distinction. PMID 8639489 references 'MT-1' in its melanoma chemoprevention data, while subsequent dose-response studies use 'Melanotan-1' to describe the identical molecule.

The peptide binds MC1R with approximately 1,000× greater affinity than endogenous alpha-MSH, triggering melanin synthesis in melanocytes through cAMP-dependent signaling. This mechanism is sequence-dependent. The D-Phe7-Arg8-Trp9 core motif is what enables stable receptor binding. Any structural modification to this region would create a distinct peptide with altered pharmacokinetics, which is why true Melanotan-1 (whether labeled MT-1 or otherwise) must match the published 13-residue sequence exactly.

Suppliers occasionally differentiate 'premium' formulations by adding descriptor terms to the base name. Phrases like 'pharmaceutical-grade Melanotan-1' or 'research-grade MT-1'. But these labels describe purity level and manufacturing standards, not chemical variants. A peptide synthesized with ≥98% purity via HPLC verification is functionally identical to one synthesized with 95% purity, assuming both match the canonical sequence. The performance difference comes from residual synthesis byproducts and acetate salt content, not from the peptide itself.

Purity Standards and What Actually Matters

When evaluating whether Melanotan-1 is 'better' than MT-1, the relevant question is: does the supplier provide third-party HPLC verification and mass spectrometry data confirming the peptide matches the published sequence? Without these assays, any claim about peptide identity is unverifiable. Real Peptides synthesizes every batch with exact amino-acid sequencing and publishes purity certificates showing residual TFA content, acetate concentration, and peptide content by mass.

Research-grade Melanotan-1 should contain ≥95% active peptide by weight, with the remainder composed of excipients like mannitol or acetate salts used during lyophilisation. Peptides below this threshold often contain truncated sequences. Missing terminal amino acids that reduce MC1R binding affinity. A 90% purity peptide isn't 10% less effective; it may be 40–60% less effective because the impurities include non-functional analogs that compete for reconstitution water without contributing biological activity.

The peptide's half-life in reconstituted solution is approximately 30 minutes at room temperature due to proteolytic cleavage at the Arg8-Trp9 bond. Refrigeration at 2–8°C extends stability to 28 days in bacteriostatic water, but freeze-thaw cycles irreversibly denature the peptide structure. Studies published in Peptides (2003) demonstrated that Melanotan-1 stored at −20°C in lyophilised form retained full potency for 36 months, while reconstituted samples lost 15% activity within 14 days at 4°C.

Supplier Variability and What 'Better' Actually Means

If Melanotan-1 and MT-1 are chemically identical, why do some research protocols report inconsistent results across batches? The answer lies in synthesis method and post-production handling. Solid-phase peptide synthesis (SPPS). The standard for research-grade peptides. Builds the chain from C-terminus to N-terminus, with each coupling step introducing potential for incomplete reactions. A peptide synthesized with 99.5% coupling efficiency at each step will have a final purity near 85%, while one synthesized at 99.9% efficiency reaches 98% purity.

Liquid-phase synthesis, used by some cost-focused suppliers, couples pre-formed peptide fragments rather than individual amino acids. This method reduces synthesis time but increases the likelihood of sequence errors. A single misincorporated amino acid in a 13-residue peptide changes the pharmacological profile entirely. Research comparing SPPS-derived Melanotan-1 to liquid-phase MT-1 found no functional difference when both matched the canonical sequence, but liquid-phase batches had 3× higher rates of sequence variants detectable via mass spec.

The most common contaminant in lower-purity Melanotan-1 is des-Nle4 Melanotan-1. A deletion analog missing the norleucine at position 4. This variant binds MC1R with approximately 40% of the affinity of full-length peptide, meaning a 10% contamination rate effectively reduces potency by 6–8%. HPLC chromatograms reveal this as a shoulder peak eluting 0.8 minutes before the primary Melanotan-1 peak, but suppliers without in-house analytics may not detect it.

Parameter	Research-Grade Standard	Below-Standard Indicator	Impact on Results
Purity (HPLC)	≥98% by peak area	<95% or no verification	Reduced potency, inconsistent dose-response
Sequence Accuracy	100% match via mass spec	Unverified or ±1 Da tolerance	Altered receptor binding, off-target effects
Lyophilisation	<5% residual moisture	>8% moisture or visible clumping	Accelerated degradation, reduced shelf life
Acetate Content	10–15% by mass	>25% or unlabeled	Falsely inflated peptide weight calculations
Storage Temperature	−20°C until reconstitution	Ambient shipping without cold packs	Partial denaturation before first use
Professional Assessment	Third-party COA with batch number	In-house testing or no documentation	Cannot verify authenticity or trace batch issues

What If: Melanotan-1 / MT-1 Scenarios

What If a Supplier Claims Their MT-1 Formula Is 'Improved' or 'Enhanced'?

Request the amino acid sequence and compare it to the published canonical structure. True Melanotan-1 has a fixed 13-residue sequence. Any modification creates a distinct peptide. If the supplier cannot provide sequence data or mass spec confirmation, the claim is unverifiable and likely marketing language rather than chemical reality. Enhanced formulations typically refer to purity level or excipient composition, not structural changes.

What If Two Suppliers Provide Conflicting Reconstitution Instructions for Melanotan-1?

Follow the protocol that specifies bacteriostatic water volume, injection technique, and refrigeration timing most precisely. Melanotan-1 requires 1–2 mL bacteriostatic water per 10mg peptide to achieve physiological concentration ranges. Protocols recommending higher dilutions may reduce peptide stability. The peptide's solubility in aqueous solution is pH-dependent, optimal at pH 5.5–6.5, so reconstitution with sterile water (pH 7.0) without buffering agents may cause gradual precipitation.

What If HPLC Data Shows 96% Purity But No Mass Spec Confirmation?

HPLC alone cannot confirm peptide identity. It measures retention time and peak area, which indicate purity but not sequence accuracy. A 96% pure sample could be 96% of a truncated analog rather than full-length Melanotan-1. Mass spectrometry is required to verify the molecular weight matches the expected 1646.85 Da for Melanotan-1 acetate salt. Request the mass spec trace or source from a supplier that provides both analyses.

The Unfiltered Truth About Melanotan-1 vs MT-1 Comparisons

Here's the honest answer: asking whether Melanotan-1 is better than MT-1 is like asking whether H2O is better than water. They're the same molecule. The framing of this as a comparison question reflects confusion propagated by inconsistent vendor terminology, not genuine chemical distinction. What actually varies between products labeled Melanotan-1 or MT-1 is synthesis precision, purity verification rigor, and supplier transparency. Not the peptide itself.

The real question researchers should ask: does this supplier provide third-party certificates of analysis with HPLC and mass spec data for every batch? Can they trace the synthesis method and confirm absence of common contaminants like des-Nle4 analogs? Without these verifications, any peptide purchase. Whether labeled Melanotan-1, MT-1, or 'pharmaceutical-grade alpha-MSH analog'. Is a trust exercise rather than a scientifically grounded sourcing decision.

We've reviewed supplier documentation across this peptide category. The pattern is consistent: suppliers emphasizing branding distinctions between Melanotan-1 and MT-1 rarely provide the analytical data that would allow independent verification. Those treating the terms as interchangeable synonyms are far more likely to publish batch-specific purity certificates.

Synthesis Quality and What Differentiates Products

The amino acid at position 4. Norleucine (Nle). Is a non-proteinogenic residue that doesn't appear in natural proteins. This substitution replaces methionine, which would otherwise undergo oxidation and reduce peptide stability. Synthesizing Nle-containing peptides requires specialized protected amino acid derivatives that cost 3–5× more than standard building blocks, which is why budget peptide suppliers occasionally substitute methionine or leucine instead. The resulting analog has reduced oxidative stability and altered lipophilicity, changing tissue distribution in vivo.

Solid-phase synthesis proceeds through repetitive cycles of deprotection (removing the temporary protecting group from the N-terminus), coupling (attaching the next amino acid), and washing (removing excess reagents). Each cycle introduces approximately 0.1–0.5% risk of incomplete coupling or side reactions. For a 13-step synthesis, cumulative yield ranges from 85% (at 99% per-step efficiency) to 98.7% (at 99.9% efficiency). The difference between good and exceptional synthesis is those fractional percentage points per step.

Post-synthesis purification uses preparative HPLC to separate full-length peptide from truncated sequences and capped (acetylated) side products. A single prep-HPLC run can increase purity from 85% crude to 98% purified, but the process removes 30–50% of the crude peptide mass as waste. Suppliers cutting costs may run fewer purification passes or use lower-resolution columns, leaving residual impurities that analytical HPLC cannot fully resolve.

Melanotan-1 is better than MT-1 only if the supplier behind the 'Melanotan-1' label maintains stricter quality controls. But that's a supplier distinction, not a chemical one. The peptide sequence defines the pharmacology. Everything else is manufacturing execution.

If you're uncertain whether a supplier's Melanotan-1 or MT-1 meets research-grade standards, compare the provided certificate of analysis to published peptide characterization data. The molecular weight should match 1646.85 Da (for acetate salt) or 1586.87 Da (for free base). HPLC retention time should fall within ±0.3 minutes of reference standards run under identical conditions. Any variance beyond analytical error suggests either sequence error or impurity interference. Both disqualifying for precision research applications where Melanotan-1 and MT-1 must mean the exact same verified compound.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-1 and MT-1 are the same peptide — an alpha-MSH analog with the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. The terms are used interchangeably in research literature, with no chemical or structural distinction. What differs between products is supplier purity verification and synthesis quality, not the peptide itself.

Research-grade Melanotan-1 should have ≥98% purity by HPLC peak area analysis, with sequence confirmation via mass spectrometry showing a molecular weight of 1646.85 Da for the acetate salt form. Peptides below 95% purity often contain truncated analogs like des-Nle4 Melanotan-1 that bind MC1R with only 40% of full-length peptide affinity, significantly reducing experimental consistency.

Reconstituted Melanotan-1 has a half-life of approximately 30 minutes at room temperature due to proteolytic cleavage at the Arg8-Trp9 bond. When stored at 2–8°C in bacteriostatic water, the peptide retains full potency for 28 days. Freeze-thaw cycles cause irreversible denaturation — lyophilised powder should remain at −20°C until reconstitution.

No — true Melanotan-1 has a fixed 13-amino-acid sequence defined in published research. Any structural modification creates a distinct peptide with altered pharmacokinetics and receptor binding. Claims of ‘enhanced’ or ‘improved’ Melanotan-1 typically refer to purity level or excipient composition, not sequence changes. Always request amino acid sequence data and mass spec confirmation to verify authenticity.

Solid-phase peptide synthesis (SPPS) builds the peptide chain one amino acid at a time with 99.9% per-step coupling efficiency, yielding 98% final purity. Liquid-phase synthesis couples pre-formed peptide fragments, reducing synthesis time but increasing sequence error rates by 3× compared to SPPS. Research-grade peptides almost exclusively use SPPS due to superior sequence accuracy and purity outcomes.

Inconsistent results typically stem from purity variations and the presence of truncated analogs like des-Nle4 Melanotan-1, which binds MC1R with 40% reduced affinity. A batch containing 10% des-Nle4 contamination effectively reduces potency by 6–8%. Without HPLC verification showing a single dominant peak at the correct retention time, peptide batches may contain multiple sequence variants that alter dose-response curves.

Norleucine at position 4 replaces methionine to prevent oxidative degradation, significantly extending peptide shelf life and stability in aqueous solution. Nle is a non-proteinogenic amino acid that maintains the hydrophobic character required for MC1R binding while resisting the sulfur oxidation that would degrade a methionine-containing peptide within days of reconstitution.

Request a certificate of analysis (COA) showing both HPLC purity data and mass spectrometry confirmation. The molecular weight must match 1646.85 Da for Melanotan-1 acetate salt. HPLC should show a single dominant peak with ≥98% area under the curve and no significant shoulder peaks indicating truncated analogs. Without both analyses, peptide identity cannot be confirmed.

Melanotan-1 reconstitution requires 1–2 mL bacteriostatic water per 10mg peptide, with gentle swirling rather than shaking to prevent foam formation. The peptide is optimally soluble at pH 5.5–6.5, so reconstitution with unbuffered sterile water may cause gradual precipitation. Inject the water slowly down the vial wall to avoid denaturing the lyophilised peptide with direct impact.

The most common contaminant is des-Nle4 Melanotan-1, a deletion analog missing the norleucine at position 4, which binds MC1R with approximately 40% of full-length peptide affinity. This appears as a shoulder peak on HPLC chromatograms eluting 0.8 minutes before the primary Melanotan-1 peak. Capped (acetylated) side products from incomplete synthesis also occur, typically comprising 2–5% of crude peptide mass before purification.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA